Overview
 |
Anthony M. Fletcher, MD, FSCAI
Moderator and Speaker
|
 |
Triston B. B. J. Smith, MD, FSCAI
Moderator and Speaker
|
 |
Tayo A. Addo, MD
Speaker
|
 |
Quinn Capers, MD
Speaker
|
 |
Karol Watson, MD, PhD
Speaker
|
 |
Alaide Chieffo, MD
Panelist
|
 |
Yolanda Hendley, MD
Panelist
|
|
|
Welcome and Introductions, Anthony M. Fletcher, MD, FSCAI
Health Equity in Cardiovascular Care: A Collaborative Call to Action, Quinn Capers, MD
Panel Discussion: Bridging the Gap Between Cath Lab, Primary Cardiology and Primary Care Providers, Triston B. B. J. Smith, MD, FSCAI; Alaide Chieffo, MD; Tayo A. Addo, MD; Yolanda Hendley, MD
Secondary ASCVD Management: Are We Making Progress? Tayo A. Addo, MD
Lp(a)? Probably Not So Little! Insights and Management Strategies, Karol Watson, MD, PhD
Call to Action: Lp(a) Testing and Screening, Anthony M. Fletcher, MD, FSCAI
Acknowledgment of Commercial Support
This activity is supported by an unrestricted educational grant from Novartis Pharmaceuticals.
Learning Objectives
Upon completion of this activity, participants will be able to:
1. Describe the importance of health equity in cardiovascular care
2. Discuss the latest advancements in managing secondary ASCVD and Lp(a) management.
3. Promote Lp(a) testing and screening as a critical component of cardiovascular health.
4. Explore strategies for improving the transition of care from the cath lab to primary cardiology
Disclosures
PLANNERS
Anthony Fletcher and Triston Smith: No relevant financial relationships with ineligible companies.
FACULTY
Tayo Addo, Quinn Capers, Anthony Fletcher, Yolanda Hendley, and Triston Smith: No relevant financial relationships with ineligible companies.
Alaide Chieffo: Boehringer Ingelheim - Advisory Board; Abbott - Advisory Board;
Karol Watson: Amgen - Consulting; Boehringer Ingelheim - Consulting; Eli Lilly - Consulting; Novartis - Consulting.
REVIEWER
Andrew Klein: No financial relationships with ineligible companies.
SCAI STAFF
Laura Porter: No financial relationships with ineligible companies.
Continuing Education Information
Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
SCAI designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful Completion
Watch the content and complete the evaluation to obtain credit.
Activity Timeline
Record date: May 1, 2025
Publish date: June 30, 2025
Retire date: April 17, 2026
SCAI's Independent Content
As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.
Planning Process
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.
Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins.
Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.
All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.
All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.
SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.
Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education.
SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.
Copyright
© 2025 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.